Patients treated with drug
RecordSTO-01M2KJ7XCG-3Y4BJ2059J-BJMGDA
Global · as of 10 Sep 2026
Patients treated with drug was more than 10,000 (Roche, published 10 September 2026).
Patients treated with drug: every country and year, and how it is measured
- Publisher
- Roche
- Authority tier
- T3 Research
- Locator
- About Enspryng (satralizumab)
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 10,000 patients.
Checked: the figure 10,000is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
Roche. (2026). U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-09-10. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA
Other formats: MLA, Chicago, BibTeX
- MLA
- Roche. "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments." 2026, https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA.
- Chicago
- Roche. "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments." 2026. https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA.
- BibTeX
- @misc{roche2026patientsbjmgda, author = {{Roche}}, title = {U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA}, note = {Original source: https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- Roche · homepage ↗
- Authority tier
- Tier 3 · Research and companies
- Report
- U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
- Type
- Press release
- Published
- 10 September 2026
- Locator
- About Enspryng (satralizumab)
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- Editorial review
- Checked on
- 15 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA